Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Revenue (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Revenue for 4 consecutive years, with $109.2 million as the latest value for Q1 2025.

  • On a quarterly basis, Revenue rose 12667.72% to $109.2 million in Q1 2025 year-over-year; TTM through Sep 2025 was $113.3 million, a 4121.12% increase, with the full-year FY2024 number at $6.6 million, up 194.81% from a year prior.
  • Revenue was $109.2 million for Q1 2025 at Century Therapeutics, up from $4.2 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $109.2 million in Q1 2025 to a low of $99000.0 in Q2 2023.
  • A 4-year average of $9.5 million and a median of $855000.0 in 2024 define the central range for Revenue.
  • Peak YoY movement for Revenue: plummeted 93.35% in 2023, then soared 12667.72% in 2025.
  • Century Therapeutics' Revenue stood at $521000.0 in 2022, then crashed by 48.56% to $268000.0 in 2023, then surged by 1457.09% to $4.2 million in 2024, then soared by 2515.96% to $109.2 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Revenue are $109.2 million (Q1 2025), $4.2 million (Q4 2024), and $791000.0 (Q3 2024).